Omni Pharmaceutical opens Fort Collin office, eyes public offering
Last Updated: 16:09 June 19, 2014
Joshua Lindenstein :
The company is largely virtual. Chief executive Bruce Schneider, the only full-time employee, is based in Pennsylvania, while many of the company’s functions are contracted out.
Omni Bio’s new headquarters is at 181 W. Boardwalk Dr. Schneider said this week that the move was made to place the company nearer to the offices of its primary investors. He said the company’s acting controller lives in Fort Collins and works out of the headquarters on a part-time basis. The company’s chief science officer, Charles Dinarello, is a professor of medicine and immunology at the University of Colorado Denver, and is leading the company’s research.
Omni Bio, which is pre-revenue, is developing a recombinant form of Alpha-1 Antitrypsin (AAT) for the treatment of a variety of inflammatory and immune-modulated diseases.
The company, which trades over the counter under the ticker symbol OMBP, in April announced a $3 million private placement funding. Schneider said Omni Bio is gearing up for a larger public offering later this year as it works to take its product to clinical testing.
More breaking news...
Amgen shutting down Boulder, Longmont sites
Mapleton property sold twice in 7 months
Colorado sees record visitor numbers in 2013
Mapleton Hill Investments LLC, registered to Don Altman, a partner of AGR
The 2013 spending figure represents an increase of 5 percent over 2012, in which the state hosted 57.9 million visitors who spent